V
40
2
FDX
54
-3
TRIP
67
-5
MCK
52
2
CNX
53
4
CVX
37
-3
MCD
46
4
SYY
52
3
SBUX
39
-4
LNC
65
2
CHD
34
-3
FSLR
40
-3
APH
64
5
LYB
37
-4
PAYX
36
3
CHRW
51
-3
ADM
56
-3
XEL
48
2
PWR
67
8
APD
52
-2
V
40
2
FDX
54
-3
TRIP
67
-5
MCK
52
2
CNX
53
4
CVX
37
-3
MCD
46
4
SYY
52
3
SBUX
39
-4
LNC
65
2
CHD
34
-3
FSLR
40
-3
APH
64
5
LYB
37
-4
PAYX
36
3
CHRW
51
-3
ADM
56
-3
XEL
48
2
PWR
67
8
APD
52
-2
Financhill
Back

Royalty Pharma PLC 10K Form

Sell
40

RPRX
Royalty Pharma PLC

Last Price:
$36.26
Seasonality Move:
-5.97%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q RPRX/Royalty Pharma PLC Quarterly
2023-11-08 10Q RPRX/Royalty Pharma PLC Quarterly
2023-08-08 10Q RPRX/Royalty Pharma PLC Quarterly
2023-05-09 10Q RPRX/Royalty Pharma PLC Quarterly
2022-11-08 10Q RPRX/Royalty Pharma PLC Quarterly
2022-08-04 10Q RPRX/Royalty Pharma PLC Quarterly

Receive RPRX News And Ratings

See the #1 stock for the next 7 days that we like better than RPRX

RPRX Financial Statistics

Sales & Book Value

Annual Sales: $2.3B
Cash Flow: $596.1M
Price / Cash Flow: 7.91
Annual Sales: $15.72
Price / Book: 2.28

Profitability

EPS (TTM): 2.34310
Net Income (TTM): $1.1B
Gross Margin: $0
Return on Equity: 10.92%
Return on Assets: 6.23%

Royalty Pharma PLC Earnings Forecast

Key Royalty Pharma PLC Financial Ratios

  • The Gross Profit Margin over the past 11 years for RPRX is 0.00%.
  • The Selling, General & Administrative Expenses for RPRX have been equal to 10.46% of Gross Profit Margin.
  • The Research & Development expenses have been 0.09% of Revenue.
  • The Interest Expense is 26.25% of Operating Income.
  • The Net Earning history of RPRX is 37.95% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 10 years.

Royalty Pharma PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RPRX
CUSIP: G7709Q
Website: royaltypharma.com

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 1.56
Quick Ratio: 1.56

Price-to-Earnings

Trailing P/E Ratio: 18.97
Forward P/E Ratio: 7.21

RPRX Technical Analysis vs Fundamental Analysis

Sell
40
Royalty Pharma PLC (RPRX) is a Sell

Is Royalty Pharma PLC a Buy or a Sell?